Akcea Therapeutics Inc Net Income per Employee (AKCA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Akcea Therapeutics Inc   (NASDAQ: AKCA)
 

Akcea Therapeutics Inc Net Income per Employee

AKCA's Quarterly Results, Trends, Rankings, Statistics
Akcea Therapeutics Inc recorded a cumulative net loss of $-42 million during 12 month ending in the second quarter 2020.
The Healthcare sector has seen employees of 121 other companies achieving higher income per employee. While Akcea Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 3324.


What is Income per Employee Ratio?






AKCA Net Income per Employee (Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -200,575 -141,377 196,966 -541,986 -697,024
AKCA's Total Ranking # 3324 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


AKCA Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 122
Healthcare Sector # 380
Overall Market # 3324

Net Income per Employee Statistics
High Average Low
$ 196,966 $ -3,412 $ -200,575
(Dec 31 2019)   (Jun 30 2020)







Companies with similar Income per Employee for 12 month ending Jun 30 2020, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2020Number of Employees Jun 30 2020


Date modified: 2026-08-29T17:40:54+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.